Business
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dup
About this update from Connect Biopharma Holdings Limited
[{"type":"image","alt":"Connect Biopharma Holdings Limited","displaySize":"","headline":null,"caption":"Connect Biopharma Holdings Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d9Dv0E8EdrX1flrzOZWuxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131","width":300,"height":83}},"lazy":false},{"type":"text","content":"– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 –","length":322,"tagName":"p"},{"type":"text","content":"– New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting –","length":309,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced clinical and preclinical data supporting rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which was presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 18-21, 2025, in San Francisco.","length":632,"tagName":"p"},{"type":"text","content":"“We are pleased to share new clinical and preclinical data highlighting rademikibart’s potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “The new analyses from our previously completed Phase 2b study not only demonstrate rademikibart’s rapid onset of acti...